Literature DB >> 15756932

Administration of myo-inositol plus ethanolamine elevates phosphatidylethanolamine plasmalogen in the rat cerebellum.

Beth Hoffman-Kuczynski1, Nicholas V Reo.   

Abstract

Plasmalogens are ether-linked phospholipids highly abundant in nervous tissue. Previously we demonstrated that acute administration of myo-inositol (myo-Ins) + [2-(13)C] ethanolamine ([2-(13)C]Etn) significantly elevated phosphatidylethanolamine plasmalogen (PlsEtn) in rat whole brain. Current experiments investigated the effects of acute myo-Ins+[2-(13)C]Etn administration on [PlsEtn] and the biosynthesis of new Etn lipids using NMR spectroscopy in rat cerebral cortex, hippocampus, brainstem, midbrain and cerebellum. Treated rats received a single dose of myo-Ins + [2-(13)C]Etn and controls received saline rather than myoIns. Data reveal that the cerebellum is the brain region most affected by treatment, which resulted in a 22% increase in [PlsEtn] and 89% increase in newly synthesized Etn lipids relative to controls (P < 0.05). Furthermore, the cerebellar PlsEtn/phosphatidylethanolamine ratio and molar percentage of PlsEtn were significantly elevated by 12% and 8%, respectively (P < 0.05). These data suggest that myo-Ins influences Etn lipid metabolism in brain, particularly in the cerebellum where there is a stimulation in the biosynthesis of new Etn lipids with a preference towards PlsEtn.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15756932     DOI: 10.1007/s11064-004-9685-4

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  32 in total

Review 1.  Plasmalogens: workhorse lipids of membranes in normal and injured neurons and glia.

Authors:  A A Farooqui; L A Horrocks
Journal:  Neuroscientist       Date:  2001-06       Impact factor: 7.519

2.  Susceptibility of plasmenyl glycerophosphoethanolamine lipids containing arachidonate to oxidative degradation.

Authors:  N Khaselev; R C Murphy
Journal:  Free Radic Biol Med       Date:  1999-02       Impact factor: 7.376

3.  Metabolism of glycerophospholipids of myelin and microsomes in rat brain. Reutilization of precursors.

Authors:  S L Miller; J A Benjamins; P Morell
Journal:  J Biol Chem       Date:  1977-06-25       Impact factor: 5.157

4.  The synthesis of choline plasmalogen by the methylation pathway in rat brain.

Authors:  R Mozzi; D Siepi; V Andreoli; G Porcellati
Journal:  FEBS Lett       Date:  1981-08-17       Impact factor: 4.124

5.  Contribution of copper binding to the inhibition of lipid oxidation by plasmalogen phospholipids.

Authors:  D Hahnel; T Huber; V Kurze; K Beyer; B Engelmann
Journal:  Biochem J       Date:  1999-06-01       Impact factor: 3.857

6.  Effects of increasing times of incomplete cerebral ischemia upon the energy state and lipid peroxidation in the rat.

Authors:  R Vagnozzi; B Tavazzi; D Di Pierro; B Giardina; B Fraioli; S Signoretti; S Distefano; M Galvano; G Lazzarino
Journal:  Exp Brain Res       Date:  1997-12       Impact factor: 1.972

7.  Phosphatidylcholine produced in rat synaptosomes by N-methylation is enriched in polyunsaturated fatty acids.

Authors:  M Tacconi; R J Wurtman
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

8.  Studies of myo-inositol and plasmalogen metabolism in rat brain.

Authors:  Beth Hoffman-Kuczynski; Nicholas V Reo
Journal:  Neurochem Res       Date:  2004-04       Impact factor: 3.996

Review 9.  The biological significance of plasmalogens in defense against oxidative damage.

Authors:  T Brosche; D Platt
Journal:  Exp Gerontol       Date:  1998-08       Impact factor: 4.032

10.  Inositol regulates phosphatidylglycerolphosphate synthase expression in Saccharomyces cerevisiae.

Authors:  M L Greenberg; S Hubbell; C Lam
Journal:  Mol Cell Biol       Date:  1988-11       Impact factor: 4.272

View more
  3 in total

1.  Evidence that plasmalogen is protective against oxidative stress in the rat brain.

Authors:  Beth Kuczynski; Nicholas V Reo
Journal:  Neurochem Res       Date:  2006-05-24       Impact factor: 3.996

2.  Plasmalogen deficiency in cerebral adrenoleukodystrophy and its modulation by lovastatin.

Authors:  Mushfiquddin Khan; Jaspreet Singh; Inderjit Singh
Journal:  J Neurochem       Date:  2008-06-07       Impact factor: 5.372

Review 3.  NADPH and Mitochondrial Quality Control as Targets for a Circadian-Based Fasting and Exercise Therapy for the Treatment of Parkinson's Disease.

Authors:  William M Curtis; William A Seeds; Mark P Mattson; Patrick C Bradshaw
Journal:  Cells       Date:  2022-08-04       Impact factor: 7.666

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.